Hanmi Pharmaceutical(364,500 -1.35%)Announced on the 12th that it announced its business direction for 2021 at the 39th JPMorgan Healthcare Conference. In this announcement, the strategy for responding to Corona 19 was revealed for the first time.
The strategy included a vision that could contribute to the end of the COVID-19 pandemic through the production of DNA and messenger ribonucleic acid (mRNA) vaccines, and development of diagnostic kits and treatments, centered on the Pyeongtaek bioplant.
Pyeongtaek Bioplant explains that it is possible to produce plasmid DNA vaccines, mRNA vaccines, and enzymes necessary for mRNA synthesis through E. coli fermentation and purification drug production facilities. Hanmi Fine Chemicals, a subsidiary, introduced that it has the capability to produce various raw materials such as nucleotides and lipids (raw materials for preparation of mRNA vaccines).
Hanmi Pharmaceutical also revealed that it is developing from prevention to diagnosis and treatment of Corona 19. Recently, the’Hanmi Cold Mask Nasal Spray’, which is based on lambdacarrageenine, which can increase the blocking effect of respiratory viral infections, was recently released. We are also preparing to release a kit that can diagnose both Corona 19 and flu at the same time.
We also derived preclinical candidates for COVID-19 treatment using the’PIKfyve’ inhibitor new drug synthetic chemicals (NCEs) and thymosin α1 hormone.
President Se-Chang Kwon said, “Hanmi Pharm has a variety of capabilities based on facilities capable of consignment production of mRNA and DNA vaccines (CMO and CDMO).” I have it.”
Hanmi Pharm is currently developing a total of 28 new drugs, including 8 metabolic diseases, 12 anticancer diseases, 5 rare diseases, and 3 other diseases.
The two new drugs developed by Hanmi Pharmaceutical are expected to receive marketing approval from the US Food and Drug Administration (FDA) this year. The neutropenia drug Rolontis, which was exported to the U.S. spectrum, and the metastatic breast cancer drug Axol, which was transferred to Artenex, are about to announce the results of the FDA’s marketing approval and priority review, respectively.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution